Vertex drug challenged by low refill rates; the FDA has issued only 4 warning or untitled letters this year; Horizon settles PBM-rebate suit
With the acquisition of VR developer BioLucid, Sharecare hopes to use empathy to encourage behavior change.
A race has emerged in a new disease space estimated to be worth billions of dollars.
Sharecare acquires virtual-reality developer; Novo Nordisk to cut 1,000 jobs; the FDA approves Medtronic's automated insulin pump
Agency networks such as BBDO, Saatchi & Saatchi, and FCB reported key pharma account wins in August, according to R3.
A new report analyzing gender parity in advertising found that men tend to endorse other men at higher rates than women. Execs share their insights about the issue.
Patient advocacy groups stay silent in drug-pricing debate; Opdivo to be tested in combination with Nektar drug; 25% of FDA employees now work for industry
A study of the social media activity of pharmaceutical firms finds that Lilly is the most active, but Novo Nordisk and Boehringer Ingelheim have better engagement.
Amgen's Kyprolis fails to best Velcade in trial; diabetes drugs have lower than average FDA approval rate; Bayer's derm business draws interest
A 2005 study estimated that 3.6 million people do not receive nonemergency medical care because they don't have access to transportation.
The agency denied Pain Therapeutics' and Durect's abuse-deterrent opioid in a complete response letter after warning the drugmakers about how they promoted the drug.
Pfizer drops plans to split into two companies; Merck's Keytruda gains competitive edge in China; Apple may be developing health software
The organizations are using innovation competitions to challenge internal and external audiences with coming up with new ideas.
Amgen's drug is set to compete with AbbVie's Humira, which is the second-best selling drug in the U.S. in 2015.
Anthem and Cigna accuse each other of violating merger terms; Alzheimer's experimental drug fails late-stage study; study calls for new approach to eradicate global epidemics
Mylan CEO comes under fire at House Committee hearing; Abbott OxyContin reps went to great lengths to sell the pain pill; UnitedHealth drops Lantus
The organization said it used Facebook to identify participants for a study designed to identify biomarkers associated with Parkinson's disease.
The consultancy includes Double Helix, which was acquired by McCann in 2012.
Drugmakers to remove incentives for sales reps marketing antibiotics; Mylan CEO defends EpiPen pricing; fitness trackers don't help people lose weight
Some physicians say they believe they have a responsibility to address the opioid epidemic, but misinformation may hinder them in that pursuit.
WebMD said David Schlanger left the company under mutual agreement, and that Steven Zatz replaced him as CEO.
Ascension worked with several Omnicom agencies on the rebranding push, including FleishmanHillard and Siegel & Gale.
GSK names new CEO; the FDA approves first Duchenne muscular dystrophy drug; Sanofi files Lantus patent lawsuit against Merck
Alexion launched a new superhero-themed awareness campaign to draw attention to four rare diseases that its products treat.
Some U.S. hospitals still haven't received Valeant discounts; U.N. General Assembly will discuss antibiotic resistance; AstraZeneca diabetes drugs lowered blood sugar in study
The app's co-founder discusses how it's educating patients and physicians about artificial intelligence and why Cardiogram is different from other heart-rate tracking apps.
The OPDP sent its second untitled letter this week, this time to Durect and Pain Therapeutics over the presentation of Remoxy ER.
The FDA approves a combination of aspirin and heartburn medication; Teva partners with Intel to develop wearable; New Mexico AG sues BMS and Sanofi
Mylan CEO to appear before House committee about EpiPen pricing; job-related health premiums rise; GSK's experimental shingles vaccine shows 90% effectiveness
Sales reps are now more likely to engage with physicians through nonpersonal promotion than in-person visits with doctors at their offices, a ZS report finds.
Patients who ask for a prescription after seeing an ad are more likely to get one; Mylan's executive pay is now under scrutiny
A new government investigation found that most but not all prices for generic drugs dispensed by Medicare Part D fell from 2010 to 2015.
For years the social network has been telling advertisers they must pay to magnify their exposure, but most continue to resist.
Drugmakers routinely pay ghostwriters to write industry-funded research articles; Horizon to buy Raptor for $800 million; WellDoc partners with J&J
The regulator cited inconsistencies with how safety trial data was recorded in a report released ahead of the advisory committee's meeting on Wednesday.
Some drugmakers employ unsettling ads; Teva said the FDA may grant quick review for generic EpiPen; Sanofi and Google's Verily partner in diabetes
Already ahead in race to first-line approval, could second-line domination be far behind for Keytruda?
One analyst envisions how a first-line approval could set up Keytruda for success in other settings.
New Cigna campaign features TV doctors; Walgreens to divest 1,000 stores; senators question Aetna's health exchange exit
A new study found that orphan drug spending will slow through 2018; senators open inquiry into Mylan; Shires launches branded campaign
The latest TV campaign from Mars features a woman with cerebral palsy joking about her love life.
The regulator charged Celator Pharmaceuticals with promoting an experimental drug as safe and effective even though it has not been approved.
The new SVP and GM of health believes that the Dentsu Aegis deal would provide scale and efficiencies.
BIO launches ad campaign defending drugmakers; GSK's experimental COPD drug reduces flare-ups in patients; NY attorney general to investigate Mylan
CEO Brent Saunders also said the drugmaker will not increase the price of drugs nearing patent expiration.
Pure Communications CEO Andrea Johnston will lead the combined agency.
MannKind plans to develop inhalable epinephrine; lawmakers accuse Mylan of evading paying higher Medicaid rebates; NICE rejects Roche's cancer drug
Approximately 10% to 15% of lung cancer patients have never smoked and have developed the disease due to genetic alterations.
Hillary Clinton releases drug-pricing plan; patent for Teva's Copaxone is invalidated; Roche's immunotherapy extends life
Shire hires Jennifer Aniston for a disease awareness campaign; critics argue that the direct-to-consumer ads for Opdivo are misleading, while Merck's Keytruda takes the lead in first-line cancer
The FDA will hold a public hearing in November to gather input on how it should regulate certain off-label communications.
Physicians are seeking beyond-the-pill services from drugmakers, but few sales reps shares details with docs about these programs, a new report finds.
Novartis to fold its cell and gene therapy business; Novo Nordisk CEO to retire; the FDA issues a safety warning for opioids taken with anti-anxiety drugs
In 2011 the drugmaker spent $9.4 million on branded ads for the EpiPen. By 2015, branded ad spending hit $43 million.
The FDA approves an Enbrel biosimilar; Express Scripts to launch program to reduce diabetes costs; a GSK vaccine beats sales forecasts
Walgreens Boots partners with PBM; Clinton proposes mental health plan; BI and Qualcomm to develop connected inhaler
The pull-back of insurance providers has left state-run health exchanges and the Obama administration facing a difficult communications challenge.
Mylan to launch generic EpiPen; the majority of NCCN guideline writers report conflicts of interest; Sanofi reports new trial data for Praluent
Sarah Jessica Parker cuts ties with Mylan over pricing controversy; lung-cancer physicians turn to Keytruda; Merck KGaA diversifies its business
Mylan offers additional copay assistance for EpiPen amid criticism; fewer doctors are seeing reps; two Copaxone patents are invalidated
The drugmaker expects the multi-channel initiative to lay its foundation in the ophthalmology market.
The anti-tobacco movement Truth is hitting young people in their pocketbooks with a new spot called "Squadless."
Retzlaff files a complaint against Turing; Pfizer to buy antibiotics from AstraZeneca; Mylan's marketing for EpiPen faces criticism
Grassley blasts Mylan over EpiPen price increases; Portola Pharmaceuticals receives CRL letter for reversal agent; the FDA approves Pfizer's opioid
Pfizer's commercial expertise in urology and oncology could help propel Medivation's Xtandi to new heights.
Pfizer to acquire cancer drugmaker Medivation; Valeant names new CFO; Apple acquires health data startup
The current reimbursement climate is more likely to impact how drugmakers order their global product launches than the U.K.'s vote to exit the E.U.
Another study finds doctors who receive gifts from drugmakers prescribe their drugs; Part D spending rose 17% in 2014; Mallinckrodt to open New Jersey site
Mergers and acquisitions targeting digital and data capabilities increased 60% to $1 billion in the first half of 2016.
Court clears Pfizer to move ahead with Remicade biosimilar; McDonald's yanks activity trackers over skin irritation; California drug-pricing bill pulled
AHIP study says half of orphan-drug usage is for non-orphan indications; Studies of GSK weight-loss pill underestimated side effects; ViiV starts HIV trial
The health site had a 44% increase in unique visitors in July 2016, compared to the same month a year ago.
The Cleveland Clinic has launched its first national men's health campaign, MENtion It, to encourage men to be more proactive about their health.
A new study published in JAMA said PCSK9 inhibitors are not worth their high prices.
OncoGenex's prostate cancer drug fails in clinical trial; Aetna to exit exchanges in 11 states; pregnant women taking acetaminophen have higher risks for their children
PhRMA and BIO, which represent life sciences firms, developed principles about sharing truthful and non-misleading information with payers and providers.
Bayer recently tapped Ken Griffey Sr. and Ken Griffey Jr. — the first father-son duo to be inducted into the Baseball Hall of Fame — as spokespeople.
Agencies are testing out strategies to reach gender parity at a time when questions of discrimination are still front and center.
Express Scripts does not disclose names of formulary board members; Endo withdrew abuse-deterrent formulation for opioid; BI to collect real-world data on Praxbind
Critics say the direct-to-consumer ad for the immuno-oncology therapy is misleading.
The company's first global consumer CMO shares the challenges of delivering global campaigns and meeting local market needs.
Study finds estimated drug costs are often overstated; physician criticizes DTC ad for Opdivo; Merck HPV ads are criticized for being manipulative
Valeant is under federal investigation; Lilly's breast-cancer drug fails to meet efficacy criteria; new policy opens up medical research of marijuana
The impending payer crackdown of the cost of MS drugs could portend the fate of other specialty drug markets, according to analysts.
Lynn Fox is suing W2O. She was laid off in March, seven months after the agency network bought her San Francisco-based boutique, Fox Communications.
A new bill exempting CME reporting gains physician support; NYT op-ed calls Opdivo DTC ad "misleading;" Valeant to sell non-core assets worth $8 billion
Valeant had deployed roughly 100 additional sales reps this year to promote Xifaxan's indication in hepatic encephalopathy.
The companies said they are also exploring opportunities to allow Cleveland Clinic experts to contribute to Verywell in the future.
Novo Nordisk attributes slow growth to biosimilars, pricing; Dentsu acquires majority stake in Merkle; AZ lung cancer drug fails late-stage trial
A massive disappointment for Bristol-Myers Squibb's Opdivo in first-line lung cancer has leveled the playfield for Merck's Keytruda.
Valeant reorganizes executive team; experimental asthma drug developed by Novartis shows promising results; Teva launches generic Gleevec
The event technology platform plans to integrate a conference note-taking app developed by AstraZeneca and DigitasLBi.
Opdivo fails to meet endpoint in new lung cancer patients; abuse-deterrent drug gets nod from FDA panel; Cephalon settles pay-for-delay case
The campaign will run in an integrated digital marketing format using channels such as Facebook, Twitter, and Youtube.
Researchers test Zika vaccine; Aetna contacts doctors who prescribe high rates of opioids; half of pediatric trials are never published or completed
The popular fitness tracker maker hired Adam Pellegrini, Walgreens' VP of digital health, to boost pharma and healthcare deals.
Express Scripts and CVS Health revealed their formularies with Pfizer's Xeljanz making the jump from excluded to preferred for Express Scripts.
Merck and Allergan reportedly vying to buy Biogen; drugmakers fight California measure capping drug prices; few seniors use the web to look for health info
The company launched a health watch, a connected scale, a blood pressure monitor, and a thermometer.
He resigned as Saatchi & Saatchi's executive chairman following his controversial remarks over gender diversity.
IBM develops chip to detect early stages of cancer; Theranos plans to develop a "minilab;" Aetna and Humana to sell $117 million in assets
- Which drugmakers have the healthiest presence on social media?
- Five things for pharma marketers to know: Monday, September 26, 2016
- Uber partners with startup to take patients to the doctor
- Drugmakers set their sights on the next potential blockbuster disease: NASH
- Five things for pharma marketers to know: Tuesday, September 27, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- When it comes to professional ads, print makes its comeback
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Five things for pharma marketers to know: Friday, September 30, 2016
- Sharecare aims to drive behavior change with VR acquisition
- Drugmakers set their sights on the next potential blockbuster disease: NASH
- Five things for pharma marketers to know: Thursday, September 29, 2016
- BBDO picks up Neulasta; FCB gains Galderma and Sandoz work in the U.S.